ABSTRACT
Thyroid-stimulating hormone receptor autoantibodies (TRAbs) are pathogenetic and diagnostic in Graves’ Disease (GD). We briefly review the value of these antibodies in GD during diagnosis, treatment, relapse and pregnancy. Currently available methods for monitoring are immunoassays for TRAbs and bioassay and immunoassay for TSI specifically.In the last 50 years several methods have been used to detect autoantibodies against TRAbs, based on bioassays or immunoassays. The bioassays measure functional activity of TRAb; cumbersome, time consuming and unsuitable for routine use in clinical laboratories. Immunoassays measure binding of the autoantibodies to the receptor without functional discrimination, are better standardised, much less expensive, and easily automatable for routine use in clinical laboratories. We briefly discuss the latest available immunoassay with discrimination of the autoantibody, i.e. Thyroid Stimulating Immunoglobulin (TSI).
ABSTRACT
<p><b>INTRODUCTION</b>In 2006, Singapore adopted the universal hepatitis B immunoglobulin (HBIg) policy. Since then, all infants of hepatitis B surface antigen (HBsAg)-positive mothers receive HBIg, irrespective of maternal hepatitis B e antigen (HBeAg) status. However, the benefits of HBIg for infants of HBeAg-negative mothers are unclear. We compared the vertical transmission rates among children of HBeAg-negative mothers who were given HBIg versus a retrospective cohort who were not given HBIg, to determine its protective effect.</p><p><b>METHODS</b>This observational study involved pregnant HBsAg-positive women seen at National University Hospital, Singapore, between June 2009 and December 2013. If the infants of these mothers completed the recommended vaccination schedule, they were recruited into the study, along with their older siblings. Serological testing for the children was performed three months after completion of the last dose of vaccine, and hepatitis B virus (HBV) surface gene sequencing was carried out if HBV DNA was detected.</p><p><b>RESULTS</b>A total of 111 infants and 47 siblings were recruited. 2 (1.5%) children were found to have vertical transmission despite receiving HBIg, while no incidences of vertical transmission were found among the historical controls who did not receive HBIg (p = 1.00).</p><p><b>CONCLUSION</b>The overall effectiveness of the hepatitis B vaccination programme for children of HBsAg-positive mothers was high, regardless of HBIg administration. The addition of HBIg did not appear to confer additional benefits, in terms of vertical transmission rate, among infants born to HBeAg-negative mothers.</p>